Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep511 | Diabetes (complications & therapy) | ECE2015

A puzzling bilateral diabetic foot problem

Denecker Nathalie , Aerden Dimitri , De Maeseneer Michel

Introduction: Charcot neuroartropathy (CN) is a devastating complication of diabetes rapidly leading to irreversible foot deformity when misdiagnosed. Differential diagnosis with foot infections and other foot-related diseases remains challenging.Case: A 58-year-old woman with type 2 diabetes was hospitalised with a red, swollen left leg and high fever. The diagnosis of erysipelas with a neuropathic wound of the first digit as the entry wound was establi...

ea0063s27.1 | What's new in reproductive endocrinology? | ECE2019

Dissecting androgens in Polycystic Ovary Syndrome (PCOS)

Walters Kirsty

Polycystic ovary syndrome (PCOS) is a common hormonal disorder characterised by reproductive hormone dysregulation involving luteinising hormone (LH) hypersecretion and hyperandrogenism, as well as reduced fertility, due to ovulatory disturbance. In addition, women with PCOS are also predisposed to metabolic disturbances such as obesity, insulin resistance, and dyslipidemia, with an increased risk of cardiovascular disease and type 2 diabetes. Currently, as the origins of PCOS...

ea0081ep881 | Reproductive and Developmental Endocrinology | ECE2022

Noonan Syndrome, Dandy-Walker variant and delayed puberty- a rare association

Lavrador Mariana , Fadiga Lu cia , Ferreira Mafalda Martins , Barros Lui sa , Paiva Isabel

Introduction: The Dandy-Walker complex (DW) comprises a rare intracranial malformation of the posterior fossa and multiple organ anomalies. The association with endocrine pathology is rare - described in isolated cases (Kallman syndrome, primary hypothyroidism (PH) and central precocious puberty). Noonan syndrome (NS) is a genetic disease usually diagnosed at birth, with variable phenotype. Most cases have AD transmission, with the PTPN11 gene mutation responsible for 50%....

ea0014eje1biog | European Journal of Endocrinology Prize Lecture | ECE2007

European Journal of Endocrinology Prize Lecture

Walker Brian

Brian Walker, UK-. AbstractBrian Walker is Professor of Endocrinology at the University of Edinburgh in Scotland where he is administrative head of a 60-strong multidisciplinary research group in the Centre for Cardiovascular Science.He graduated in medicine in Edinburgh in 1986 and completed his clinical training in Glasgow and Edinburgh. Since 1996 he has practised as an honorary consultant i...

ea0013s7biog | Society for Endocrinology Medal Lecture | SFEBES2007

Society for Endocrinology Medal Lecture

Walker Brian

Brian Walker, University of Edinburgh, Edinburgh, United Kingdom. AbstractBrian Walker is Professor of Endocrinology at the University of Edinburgh, where he is administrative head of a 60-strong multidisciplinary research group in the Centre for Cardiovascular Science.He graduated in medicine in Edinburgh in 1986 and completed his clinical training in Glasgow and Edinburgh. Since 1996 he has pra...

ea0011s90 | Contrasting practices in European endocrinology | ECE2006

New endocrinology medicines: when are they good value?

Walker A

Health care payers (governments or insurance plans) are increasingly challenging new health services, including medicines, to prove their value and several European countries have established agencies to help with this task. The example of NICE in England is one example but the Scottish Medicines Consortium (SMC) offers another.In its first four years the SMC has considered 14 endocrinology products, accepting eleven for use (79%). Manufacturers submit e...

ea0005s27 | Prolactin: Novel Aspects | BES2003

PRL and its antagonist: The yin and yang of growth versus differentiation

Walker A

PRL has long been recognized as a hormone that regulates both cell proliferation and differentiation in the mammary gland. Current theory proposes that it is the coexisting steroidal environment which dictates whether PRL is mainly proliferative, as it is during pregnancy, or mainly differentiative, as it is during lactation. While major changes in the steroidal environment may contribute to a shift in response by the mammary gland, other tissues which show both responses to P...

ea0050p322 | Obesity and Metabolism | SFEBES2017

Cholestatic pregnancy alters the gut incretin response to diet, affecting GLP-1, PYY and FGF19 secretion, with reversal of changes associated with ursodeoxycholic acid treatment

Ovadia Caroline , Chambers Jenny , Martineau Marcus , Murphy Kevin , Walters Julian , Williamson Catherine

Introduction: Intrahepatic cholestasis of pregnancy (ICP) is characterised by maternal pruritus and raised serum bile acids, and is associated with adverse fetal outcomes (e.g. preterm birth, neonatal unit admission and stillbirth). Maternal metabolic impacts include higher rates of gestational diabetes mellitus, hypertriglyceridaemia and hypercholesterolaemia. Glucose and lipid metabolism are influenced by gut incretin release, and bile acids are ...

ea0050p322 | Obesity and Metabolism | SFEBES2017

Cholestatic pregnancy alters the gut incretin response to diet, affecting GLP-1, PYY and FGF19 secretion, with reversal of changes associated with ursodeoxycholic acid treatment

Ovadia Caroline , Chambers Jenny , Martineau Marcus , Murphy Kevin , Walters Julian , Williamson Catherine

Introduction: Intrahepatic cholestasis of pregnancy (ICP) is characterised by maternal pruritus and raised serum bile acids, and is associated with adverse fetal outcomes (e.g. preterm birth, neonatal unit admission and stillbirth). Maternal metabolic impacts include higher rates of gestational diabetes mellitus, hypertriglyceridaemia and hypercholesterolaemia. Glucose and lipid metabolism are influenced by gut incretin release, and bile acids are ...

ea0019p286 | Reproduction | SFEBES2009

Inhibin B and AMH are NOT predictors of serum testosterone in young men after cancer

Greenfield DM , Walters SJ , Ross RJM , Coleman RE , Hancock BW , Snowden JA , Ledger WL

Background: In men inhibin B is correlated with sperm count, concentration and testicular volume. Anti-müllerian hormone (AMH) is significantly positively correlated with inhibin B and significantly negatively correlated with FSH. Raised FSH is a traditional marker of infertility. Young male cancer patients treated with gonadotoxic agents are at high risk of hypogonadism (HG). The relationship between inhibin B and AMH with serum total testosterone is unclear.<p class...